$SCYX I'm out. I think they should stay focused on the antifungal space. Also, $RGLS was developing a treatment targeting the root cause of ADPKD, which looked promising and Novartis acquired them. I still have exposure to that drug through CVRs.
$SLS Get a kick out of the childish bro basher trying to say I missed out on $RGLS. I bought at $0.93 and made a massive profit when it got bought out. Oh, and how cute, I have $SLS on my post as well.
Stop blind hating $SLS board. If you believe in the product, believe in the product. If you attack Bulls that have simple questions, you put off scammish vibes and raise more questions. $SLS doesn't need that right now. Do better.
@Heypentaco Hey lil guy. Mornin' sunshine. And I didn't miss $RGLS. Thanks for the reminder. Another winning pick from @BioRich. Also, since you're obviously a short brain, I've been Bullish on $SLS for over 2 years. Your week bro attack is laughable. Do better.
Oh, and what "indicator" are you referring to that you're so proud of?
TheRealShortSqueezy
@TheShortSqueezy
·
6s
$ATAI: Recent News Strengthens Analyst Conviction
ATAIBeckley is seeing increasing analyst conviction following the release of key clinical milestones and recent business developments.
Latest Analyst Update:
HC Wainwright & Co. has maintained its Buy rating on ATAI while raising its price target to $25.00 from $15.00, a 66.67% increase.
Recent Analyst Coverage:
Guggenheim – $11 price target (Jan 20, 2026)
JonesTrading – $16 price target
Canaccord Genuity – PT raised to $14 from $11 (+27%)
Needham – $12 price target
Institutional Activity:
ARK Invest increased its position in Q4 2025 by 1,286,446 shares (+63.7%)
ARK now holds 3,305,997 shares.
Rising price targets, institutional buying, and continued execution reflect growing confidence in ATAIBeckley’s strategy and long-term potential. 📊
Communicated disclaimer: https://bit.ly/4ci8Ftu
Sector Peers: $RLMD $SLS $ANIX $RGLS
$RLYB it's still tracking the $RGLS example (which got bought out a month after their data) within a few percentage points. RGLS was 1.40 pre-data....5 days after $2, two weeks later $4, and then a week later $8 buyout for a total of 4 weeks post-data.
Next stops for us IMO, I assume news within Q1 (by March 31):
$7 --> $10 --> $15 and then announcement (buyout / PIPE / partnership) --> $30+
$ATAI Delivers Major Development News🔬🧬
ATAI Life Sciences continues advancing its clinical pipeline following multiple recent milestones.
Recent Key Milestones 🎯
The company has reported several important advancements across its pipeline and leadership:
➡️Positive Phase 2a topline results for EMP-01 in social anxiety disorder, providing early clinical proof-of-concept
➡️Continued development of core pipeline assets, including:
🥇BPL-003: progressing toward late-stage development
🥈VLS-01: currently in Phase 2 clinical trials
➡️Strengthened executive leadership with the appointment of a new Chief Financial Officer
These developments highlight accelerating pipeline momentum heading into 2026
Investor Conferences 👇
🗓️March 4th: TD Cowen 46th Annual Health Care Conference
🗓️March 10th: Jefferies 2026 Biotech on the Beach
🗓️March 11th: Leerink Global Healthcare Conference
Communicated Disclaimer : https://bit.ly/3OCJhol
Sector Peers: $SLS $ANIX $RGLS $VNDA
$RLYB cont. from post below.
4). Data released Feb 14. Good efficacy and safety. Now company can talk again and is out of 'black period' . Now that they know plan going forward they can now share data with potential investors (PIPE theory) and/or suitors (parnter/buyout theory). Hence the 'clock' started on Feb 17. From Jan to Feb 17 they did not even know the future of their own company. Makes no sense that they would be sharing data w/ investors at this point.
5). Since data: Stock has rallied almost 50% . Constant buying pressure and volume pushing stock up to closer and closer to intrinsic value. Following the $RGLS example. Data , no reaction, then price adjustment. Then the buyout came for $RGLS a month later. Investors are just now seeing the data for the first time and a deal should take 30-60 days to complete. Expecting something soon . Price action seems to corroberate my theory as well. GLTA !
$VTYX [Correct] Congratulations to those who listened from $1.0-1.7. You only had to wait 6-12mos. Concurrently-you could have done well from my analyses on $RANI from $0.4, $IMRX from $1.0, SCNX from $0.5->3.0, $RGLS from $0.8, $VKTX from $17. Again-invest to your own risk tolerance and time horizon, diversify your positions and do your own analysis to build your conviction.
https://www.investing.com/news/stock-market-news/ventyx-biosciences-stock-surges-after-eli-lilly-acquisition-talks-93CH-4433423
$COCH So far this year, I have cited $RANI at $0.4, $VTYX from $1.0-1.7, $IMRX from $1.5 and $RGLS from $0.8. You can burn through my post history to confirm each one. COCH is yet another Company (IMO) with tremendous upside from its current valuation. 50-100% upside just to reach institutional equity placements, while success on Acclaim study makes this 5-10X more valuable (IMO). The Company is trading at/around its ATL, Oversold and Undervalued. The balance sheet has been strengthened materially by debt elimination and equity placements, as-noted. Pivotal trial underway while COCH builds its global IP.
$SLS My most notable ( to me ) indicator of a buyout went off here about 3 months ago. It is usually 3 to 6 month thereafter that I start really watching for the announcement. Check out $RGLS . The indicator held true there. Enjoy what my opinion says is coming here. The CEO ... playing with big dogs on LinkedIn? LOL...Duh.
